Rami Ahmed

Rami Ahmed

Auto-generated profile, based on publicly available information

Rami Ahmed

Infectious Disease Nanomedicine Research Group, School of Pharmacy, University of the Western Cape, Robert Sobukwe Road

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2021 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
RARami Ahmed
Rami Ahmed
MAMarique Aucamp
Marique Aucamp
NENaushaad Ebrahim
Naushaad Ebrahim
HSHalima Samsodien
Halima Samsodien

6 May 2025 in Artificial Cells, Nanomedicine, and Biotechnology
Verified
Journal Article
Open access
PDPrince N. Dlozi
Prince N. Dlozi
RARami Ahmed
Rami Ahmed
SKStar Khoza
Star Khoza
ADADMIRE DUBE
ADMIRE DUBE
Tuberculosis (TB), primarily caused by Mycobacterium tuberculosis, remains a global health burden. Current antibiotic treatments are limited by adverse effects, poor adherence, and drug resistance, necessitating new therapeutic approaches. Recent studies highlight the role of vitamin D3 (VD3) in enhancing host immune responses against the mycobacterium via cathelicidin (an antimicrobial peptide) and autophagy activation. In this study, VD3-loaded poly-ƹ-caprolactone (PCL) nanoparticles (NPs) were synthesized to enhance cathelicidin expression in macrophages. NPs containing cholecalciferol, calcifediol, and calcitriol were synthesized using an emulsification solvent-evaporation technique. Average sizes of synthesized NPs ranged from 304.7 to 458.7 nm, with polydispersity index (PDI) and zeta potential (ZP) ranging from 0.103 to 0.257 and -17.3 to -7.47 mV, respectively. Encapsulation efficiencies were 9.68%, 10.99%, and 19.28% for cholecalciferol, calcifediol, and calcitriol, respectively. VD3-encapsulated NPs stimulated a dose-dependent increase in cathelicidin expression in THP-1 macrophages. Encapsulated calcifediol and calcitriol (100 ng/ml) induced the expression of 243.46 ng/ml ± 4.55 ng/ml and 396.67 ng/ml ± 25.24 ng/ml of cathelicidin, respectively, which was significantly higher than that induced by the free drugs. These findings suggest that NP encapsulation may offer a more efficient approach to using vitamin D3 for inducing cathelicidin expression as a host-directed treatment for TB.

26 November 2024 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
RARami Ahmed
Rami Ahmed
MAMarique Aucamp
Marique Aucamp
HSHalima Samsodien
Halima Samsodien

8 June 2026 in Journal of Biomaterials Science, Polymer Edition
Verified
Journal Article
Open access
JMJames Mwajombe
James Mwajombe
RARami Ahmed
Rami Ahmed
RMRetsepile E. Maphasa
Retsepile E. Maphasa
CRClarence Rubaka
Clarence Rubaka
NYNateiya M. Yongolo
Nateiya M. Yongolo
ADADMIRE DUBE
ADMIRE DUBE
Cerebral malaria (CM) is a severe neurological complication of Plasmodium falciparum infection associated with endothelial activation, neuroinflammation, and disruption of the blood-brain barrier (BBB). While curcumin (Cur) possesses antiplasmodial and anti-inflammatory properties, its therapeutic potential is limited by poor aqueous solubility, rapid metabolism, and insufficient brain bioavailability. In this study, we hypothesized that polysaccharide-driven surface engineering could regulate nanoparticles (NPs) interfacial properties to improve BBB compatibility and antiplasmodial efficacy. Cur-loaded polycaprolactone (PCL) NPs were fabricated through a single-emulsion solvent evaporation technique and sequentially coated with chitosan (CS) and hyaluronic acid (HA) to establish defined structure-property relationships. The resulting nanoformulations were characterized for particle size, surface charge, polysaccharide deposition, encapsulation efficiency (EE), and release kinetics. In-vitro biological performance was evaluated through hemocompatibility, brain endothelial cell viability, BBB integrity through transendothelial electrical resistance measurements, and in-vitro antiplasmodial activity against P. falciparum FCR3. Dual polysaccharide coating produced stable NPs with controlled size, enhanced surface charge, sustained Cur release, and significantly improved endothelial compatibility compared with free Cur and non-hyaluronic-acid formulations. Notably, HA coating strengthened BBB integrity and enhanced antiplasmodial potency. These findings demonstrate that CS- HA surface functionalization governs critical structure-property relationships, highlighting the potential of polysaccharide-engineered nanocarriers for adjunctive CM drug delivery.

14 April 2026 in Nanomedicine
Verified
Journal Article
Closed access
YAYohana Amos
Yohana Amos
RARami Ahmed
Rami Ahmed
ESElingarami Sauli
Elingarami Sauli
CRClarence Rubaka
Clarence Rubaka
MTMgeni Mohammed Tambwe
Mgeni Mohammed Tambwe
ADADMIRE DUBE
ADMIRE DUBE
Malaria remains a major global health burden, particularly in sub-Saharan Africa. Although quinine (QN) is an effective antimalarial, its clinical application is limited by dose-dependent toxicity from nonspecific biodistribution. This study developed heparin-functionalized PCL nanoparticles (Hep-QN-PCL) to target Plasmodium falciparum-infected RBCs and enhance QN's therapeutic efficacy. QN-loaded PCL nanoparticles were formulated using a double emulsion solvent evaporation technique, followed by chitosan-mediated heparin conjugation. They were evaluated for physicochemical properties, in vitro drug release, hemolysis, cytotoxicity, targeting, and antiplasmodial activity against FCR3 Plasmodium falciparum. Optimized Hep-QN-PCL nanoparticles (353.2 ± 16.8 nm, PDI 0.252, zeta +20.8 ± 1.9 mV, encapsulation 77.9%) showed successful Hep conjugation as confirmed through FTIR and thermal analysis, sustained QN release over 96 h via Fickian diffusion, and enhanced release under iRBC-mimicking conditions. They were hemocompatible (527 µg/mL vs. 195.7 µg/mL for free QN), and demonstrated increased iRBC targeting (partition 8.50 ± 0.30 vs. 4.20 ± 0.12). Hep-QN-PCL achieved ~5.3-fold higher antiplasmodial potency (IC50 = 23.33 ng/mL vs. 122.86 ng/mL) and 14.2-fold greater selectivity index (22.60 vs. 1.59). These findings demonstrate a targeted nanomedicine platform with improved efficacy and safety for malaria therapy, suitable for further preclinical studies.